FMS logo

FMS Total Costs & Expenses

Latest reported€17.54B EUR
FMS TTM Total Costs & Expenses · EUR (€0.00 → €17.54B)
High-resolution chart · PNG

FMS total costs & expenses history

Trailing twelve months (TTM) · EUR. Each value covers four complete reported quarters.

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) Total Costs & Expenses — Trailing twelve months (TTM) (EUR)
Period endingTotal Costs & Expenses (EUR)
17,535,042,000
17,537,643,000
17,800,777,000
17,966,022,000
17,880,357,000
17,824,045,000
17,802,828,000
17,677,215,000
17,991,749,000
18,118,749,000
18,083,240,000
18,167,868,000
18,180,391,000
18,128,561,000
17,886,262,000
17,439,263,000
16,751,445,000
16,231,224,000
15,766,395,000
15,507,105,000
15,352,388,000
15,357,860,000
15,554,654,000
15,579,675,000
15,644,308,000
15,600,543,000
15,283,917,000
15,007,317,000
14,719,622,000
14,524,252,000
14,405,212,000
14,644,212,000
14,825,685,000
15,074,058,000
15,488,784,000
15,275,814,200
15,062,820,868
14,561,989,926
13,900,532,280
13,567,170,780
13,263,062,622
13,115,142,404
13,061,540,307
12,692,531,567
12,247,462,726
11,393,193,349
10,473,237,881
9,637,638,612
9,167,667,359
9,127,762,156
9,175,332,097
9,190,879,008
9,102,505,790
8,999,902,958
8,745,050,806
8,954,397,144
8,690,272,894
8,285,600,227
8,056,858,647
7,769,008,949
7,695,288,302
7,871,365,195
7,862,094,546
7,630,670,639
7,413,093,555
7,048,645,393
6,848,319,924
6,672,606,576
6,633,135,124
6,382,074,329
6,095,279,378
5,769,805,176
5,566,978,072
5,633,216,804
5,753,090,012
5,731,085,729
5,794,636,407
5,711,088,728
5,486,979,746
5,476,506,119
5,220,772,611
5,002,746,102
4,834,217,645
4,265,708,660
4,131,472,938
4,044,060,037
3,995,924,459
3,980,797,802
3,925,091,160
3,854,401,682
3,865,791,788
4,029,085,693
4,122,073,006
4,185,499,626
4,312,479,705
5,014,343,592
5,051,080,719
5,178,622,616
5,160,889,182
4,338,812,597
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.